Development stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research to treat PTSD, Alzheimer’s disease, and other neurological disorders Silo Pharma Inc. (OTCMKTS: SILO) has extended its exclusive option agreement for homing peptides with the University of Maryland, Baltimore to explore a novel invention called ‘Joint-homing peptides.’
These novel peptides are being developed to be used in the investigation and treatment of arthritogenic processes. The targeted homing peptides possess ability in inflamed endothelium which suggests they can be used to deliver therapeutics to specific disease joints.
This method can be used to enhance the therapeutic effect of current and future therapeutics and decrease potential systemic toxicity.
In addition, the homing peptides also have the potential for the development of fusion imaging molecules and nanoparticles to study the arthritic pathogenesis. They can also be used to treat autoimmune diseases.
“This extended option gives Silo further time and studies to access to a and confirm a potentially vital therapeutic that can also act as a drug delivery platform. The ability to deliver therapeutics directly to targeted areas of the body could be revolutionary. The Joint-homing peptides have shown increased efficacy of treatment while reducing the amount of medication needed while also reducing harmful effects of treatment. There is a tremendous need for creative and unique therapeutics for patients suffering from rare diseases,” said the CEO of Silo Pharma, Eric Weisblum.